To further validate the hypothesis of the oncogenic potency and the molecular action of LMO3 in NKTCL, further in vitro, in vivo, and clinical studies are needed and will be carried out in our future study. This evidence concerns the gene LMO3 and extranodal nasal NK/T cell lymphoma.